SDKI Inc. published a new report on the antibiotic market on January 25, 2022. This study includes the statistical and analytical approaches needed to grow the antibiotic market. The key industry insights provided in the report provide readers with better ideas about market overviews regarding existing market scenarios. In addition, the report contains a detailed discussion of current and future market trends related to market growth.
The antibiotic market is estimated to reach US $ 87.36 billion by 2031, from a market value of US $ 52.39 billion in 2022, and is expected to grow at a CAGR of 6.6% during the 2022-2031 forecast period.
https://www.sdki.jp/press-details/antibiotic-market/618
The number of individuals suffering from chronic diseases is increasing all over the world. According to the World Health Organization (WHO), chronic illness accounts for more than 60% of all deaths. That is, 36 million of the 57 million deaths worldwide have died. Antibiotics are increasingly being used to manage infectious and chronic diseases such as asthma, cystic fibrosis, and COPD. As a result, as the incidence of chronic diseases increases, the demand for antibiotics is likely to increase for the treatment of these conditions.
In addition, numerous national and international initiatives aimed at financially encouraging antibiotic research and development activities are on the rise. Some of the major initiatives include the New Drug (ND4BB) program for bad bugs with the Innovative Drug Initiative (IMI) and the Joint Programming Initiative (JPIAMR) on Antimicrobial Resistance. These types of initiatives will support the growth of the antibiotic market during the forecast period. However, growing concern about antibiotic abuse could curb the growth of the antibiotic market during the forecast period.
Antibiotic Market Segment
The antibiotic market is divided by type of inhibitor (protein synthesis, cell wall, DNA, RNA), by drug class (fluoroquinolone, cephalosporin, penicillin, macrolide, carbapenem, aminoglycoside), and by region. Will be done. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.
Based on the type of inhibitor, the antibiotic market is divided into protein synthesis, cell walls, DNA, RNA, and other inhibitors. The cell wall segment has the highest market share in the overall market. In 2019, this segment has a 42% share of the overall market and is projected to dominate the antibiotic market. This drug class includes antibiotics such as penicillin, cephalosporins and carbapenem. These are one of the most important groups of antibiotics and show maximum activity against Gram-positive and Gram-negative bacteria. This is driving the growth of this segment.
Regional Overview of the Antibiotic Market
The Asia-Pacific region has the largest share of the antibiotic market. In 2019, the region gained a share of about 47% of the total market. The growing prevalence of infectious diseases and chronic diseases, as well as the growing interest of global players in investing in this market, is supporting the growth of the antibiotic market in the region. Meanwhile, the antibiotic markets in North America and Europe are expected to grow at a considerable rate during the forecast period. This growth is due to favorable reimbursement policies, increased demand for branded therapies, and increased R & D activity.
These regional segments are North America (US and Canada); Asia Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Singapore, Other Asia Pacific); Latin America (Brazil, Mexico, Argentina, etc.) Latin America); Middle East and Africa (Israel, GCC [Saudi Arabia, Arab Emirates, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, and other Middle East and Africa) and Europe (UK, Germany, France, Italy) , Spain, Hungary, Belgium, Netherlands, Luxemburg, NORDIC, Poland, Turkey, Russia and other Europe) and more.
Key Players in the Antibiotic Market
Key players in the antibiotic market include Novartis AG, Johnson & Johnson, Pfizer, Inc., GlaxoSmithKline, Bayer AG and AstraZeneca. The study includes a detailed competitive analysis of these major companies in the antibiotic market, corporate profiles, recent developments, and key market strategies.
Report sample URL
https://www.sdki.jp/sample-request-53290
SDKI Inc. Company profile
SDKI Inc.'s goal is to uncover market scenarios for different countries such as Japan, China, the United States, Canada, the United Kingdom and Germany. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With SDKI gaining trust and a customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.
https://www.sdki.jp/press-details/antibiotic-market/618
The number of individuals suffering from chronic diseases is increasing all over the world. According to the World Health Organization (WHO), chronic illness accounts for more than 60% of all deaths. That is, 36 million of the 57 million deaths worldwide have died. Antibiotics are increasingly being used to manage infectious and chronic diseases such as asthma, cystic fibrosis, and COPD. As a result, as the incidence of chronic diseases increases, the demand for antibiotics is likely to increase for the treatment of these conditions.
In addition, numerous national and international initiatives aimed at financially encouraging antibiotic research and development activities are on the rise. Some of the major initiatives include the New Drug (ND4BB) program for bad bugs with the Innovative Drug Initiative (IMI) and the Joint Programming Initiative (JPIAMR) on Antimicrobial Resistance. These types of initiatives will support the growth of the antibiotic market during the forecast period. However, growing concern about antibiotic abuse could curb the growth of the antibiotic market during the forecast period.
Antibiotic Market Segment
The antibiotic market is divided by type of inhibitor (protein synthesis, cell wall, DNA, RNA), by drug class (fluoroquinolone, cephalosporin, penicillin, macrolide, carbapenem, aminoglycoside), and by region. Will be done. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.
Based on the type of inhibitor, the antibiotic market is divided into protein synthesis, cell walls, DNA, RNA, and other inhibitors. The cell wall segment has the highest market share in the overall market. In 2019, this segment has a 42% share of the overall market and is projected to dominate the antibiotic market. This drug class includes antibiotics such as penicillin, cephalosporins and carbapenem. These are one of the most important groups of antibiotics and show maximum activity against Gram-positive and Gram-negative bacteria. This is driving the growth of this segment.
Regional Overview of the Antibiotic Market
The Asia-Pacific region has the largest share of the antibiotic market. In 2019, the region gained a share of about 47% of the total market. The growing prevalence of infectious diseases and chronic diseases, as well as the growing interest of global players in investing in this market, is supporting the growth of the antibiotic market in the region. Meanwhile, the antibiotic markets in North America and Europe are expected to grow at a considerable rate during the forecast period. This growth is due to favorable reimbursement policies, increased demand for branded therapies, and increased R & D activity.
These regional segments are North America (US and Canada); Asia Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Singapore, Other Asia Pacific); Latin America (Brazil, Mexico, Argentina, etc.) Latin America); Middle East and Africa (Israel, GCC [Saudi Arabia, Arab Emirates, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, and other Middle East and Africa) and Europe (UK, Germany, France, Italy) , Spain, Hungary, Belgium, Netherlands, Luxemburg, NORDIC, Poland, Turkey, Russia and other Europe) and more.
Key Players in the Antibiotic Market
Key players in the antibiotic market include Novartis AG, Johnson & Johnson, Pfizer, Inc., GlaxoSmithKline, Bayer AG and AstraZeneca. The study includes a detailed competitive analysis of these major companies in the antibiotic market, corporate profiles, recent developments, and key market strategies.
Report sample URL
https://www.sdki.jp/sample-request-53290
SDKI Inc. Company profile
SDKI Inc.'s goal is to uncover market scenarios for different countries such as Japan, China, the United States, Canada, the United Kingdom and Germany. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With SDKI gaining trust and a customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.
